Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 12, 2020 4:01 PM EDT- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed -
- GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms -
- GB004 completed successful Phase 1b in ulcerative colitis; Phase 2 trial planned to commence in 2020 -
- GB004 license agreement with Aerpio amended to provide financial, milestone and royalty benefit to Gossamer -
- Chief Medical Officer Jakob Dupont, M.D. to depart Gossamer; will... More
